Earnings Feed
Start Free
NEOGENOMICS INC·4

Mar 3, 6:16 PM ET

Olivo Alicia C 4

4 · NEOGENOMICS INC · Filed Mar 3, 2026

Research Summary

AI-generated summary of this filing

Updated

Neogenomics (NEO) EVP Alicia Olivo Receives Options & RSUs

What Happened

  • Alicia C. Olivo, EVP, General Counsel & Business Development of Neogenomics (NEO), was granted two equity awards on March 1, 2026: 147,804 stock options and 89,013 restricted stock units (RSUs). The Form 4 reports these as awards (derivative grants) with a reported acquisition price of $0.00 because they were granted as compensation rather than purchased.
  • The stock options are described as premium-price options (the filing says the exercise price was calculated at 110% of a recent closing price — per the filing, using the February 27, 2026 close). The RSUs convert to common shares upon vesting; neither award involved an immediate cash purchase or sale.

Key Details

  • Transaction date: March 1, 2026; Filing date: March 3, 2026 (timely).
  • Awards: 147,804 stock options; 89,013 restricted stock units. Reported acquisition price: $0.00 (compensation grant).
  • Vesting: Both the options and RSUs vest ratably over the first three anniversary dates following the grant (per filing footnotes).
  • Exercise price note: Options were granted as premium-price options (exercise price set at 110% of the referenced closing price).
  • Shares owned after transaction: Not specified in the summary data provided.
  • No sale, purchase, exercise, or tax-withholding transaction reported in this filing — this is a standard compensation grant (Form 4 transaction code A).

Context

  • These are compensation awards, not open-market purchases or sales. Because the options are premium-priced (strike above the referenced market price), they have less intrinsic value at grant than at-the-money options and require stock appreciation above the strike to be valuable.
  • RSUs vest over time and convert to common shares when vested; such grants are common for executive retention and compensation and do not by themselves indicate insider buying or selling sentiment.

Insider Transaction Report

Form 4
Period: 2026-03-01
NEOGENOMICS INCNEO
Olivo Alicia C
EVP, GC & Business Development
Transactions
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-01+147,804→ 147,804 total
    Exercise: $10.81Exp: 2036-03-01→ Common Stock (147,804 underlying)
  • Award

    Restricted Stock Unit

    [F3][F4]
    2026-03-01+89,013→ 89,013 total
    Exercise: $0.00→ Common Stock (89,013 underlying)
Holdings

  • Common Stock

    93,224

  • Stock Option (Right to Buy)

    [F5]
    Exercise: $19.12Exp: 2026-09-30→ Common Stock (1,046 underlying)
    1,046

  • Stock Option (Right to Buy)

    [F6]
    Exercise: $27.34Exp: 2027-05-01→ Common Stock (1,024 underlying)
    1,024

  • Stock Option (Right to Buy)

    [F7]
    Exercise: $48.99Exp: 2028-05-01→ Common Stock (516 underlying)
    516

  • Stock Option (Right to Buy)

    [F8]
    Exercise: $46.10Exp: 2028-08-01→ Common Stock (1,117 underlying)
    1,117

  • Stock Option (Right to Buy)

    [F9]
    Exercise: $9.45Exp: 2029-05-01→ Common Stock (22,222 underlying)
    22,222

  • Stock Option (Right to Buy)

    [F10]
    Exercise: $10.05Exp: 2029-09-01→ Common Stock (46,355 underlying)
    46,355

  • Stock Option (Right to Buy)

    [F11]
    Exercise: $19.65Exp: 2030-05-11→ Common Stock (36,508 underlying)
    36,508

  • Performance Stock Unit

    [F12][F4]
    Exercise: $0.00From: 2026-05-11→ Common Stock (19,508 underlying)
    19,508

  • Restricted Stock Unit

    [F13][F4]
    Exercise: $0.00→ Common Stock (6,503 underlying)
    6,503

  • Stock Option (Right to Buy)

    [F14]
    Exercise: $16.45Exp: 2034-02-23→ Common Stock (42,344 underlying)
    42,344

  • Performance Stock Unit

    [F15][F4]
    Exercise: $0.00From: 2027-02-23→ Common Stock (25,330 underlying)
    25,330

  • Restricted Stock Unit

    [F16][F4]
    Exercise: $0.00→ Common Stock (8,443 underlying)
    8,443

  • Restricted Stock Unit

    [F4]
    Exercise: $0.00From: 2026-01-13→ Common Stock (59,382 underlying)
    59,382

  • Stock Option (Right to Buy)

    [F17][F18]
    Exercise: $13.05Exp: 2035-02-21→ Common Stock (107,450 underlying)
    107,450

  • Restricted Stock Unit

    [F19][F4]
    Exercise: $0.00→ Common Stock (42,159 underlying)
    42,159
Footnotes (19)
  • [F1]This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 27, 2026 and multiplied by 110%.
  • [F10]On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  • [F11]On May 11, 2023, Ms. Olivo was granted 36,508 stock options. The options vest ratably over the first three anniversary dates of the grant date.
  • [F12]On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.
  • [F13]On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
  • [F14]On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.
  • [F15]On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
  • [F16]On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
  • [F17]This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.
  • [F18]On February 21, 2025, Ms. Olivo was granted 107,450 stock options. The options vest ratably over the first three anniversary dates of the grant date.
  • [F19]On February 21, 2025, Ms. Olivo was granted 63,238 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
  • [F2]On March 1, 2026, Ms. Olivo was granted 147,804 stock options. The options vest ratably over the first three anniversary dates of the grant date.
  • [F3]On March 1, 2026, Ms. Olivo was granted 89,013 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
  • [F4]Once vested, the shares of common stock are not subject to expiration.
  • [F5]On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  • [F6]On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  • [F7]On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  • [F8]On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  • [F9]On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.
Signature
/s/ Alicia C. Olivo|2026-03-03

Documents

1 file
  • 4
    wk-form4_1772579782.xmlPrimary

    FORM 4